H Lundbeck A/S(HLUN-A) News

Date	Title
Jun 21	New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine
Oct 14	Lundbeck to acquire Longboard Pharmaceuticals in $2.6B deal